SREBF1 and cancer: Furthermore, we demonstrated that the inhibition of SREBP-1 by fatostatin or through shRNA- or miRNA (hsa-miR-497-5p)-mediated regulation increased the sensitivity of cisplatin-resistant cells to cisplatin and suppressed the cancer stemness of lung cancer cells.